Assaying the potency of influenza vaccines

Vaccines

Volumn 3, Issue 1, 2015, Pages 90-104

  Minor, Philip D ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Essential Regulatory Laboratories; Influenza Collaborating Centres; Influenza vaccine; Potency; Reagent calibration; SRD

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS ANTIGEN;

ANTIGEN ANTIBODY REACTION; BINDING AFFINITY; BIOASSAY; CALIBRATION; DOSE RESPONSE; DRUG POTENCY; HUMAN; IMMUNODIFFUSION; IMMUNOGENICITY; NONHUMAN; PATHOGENESIS; REVIEW; VALIDATION PROCESS;

EID: 84941879338     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3010090     Document Type: Review

References (35)

1. Shortridge, K.F. Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: Abridged chronology and virus isolation. Vaccine 1999, 17, S26–S29.
2. Chan, P.K. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin. Infect. Dis. 2002, 34, S58–S64.
3. Centers for Disease Control. The 2009 H1N1 Pandemic: Summary Highlights, April 2009–April 2010. Available online: http://www.cdc.gov/h1n1flu/cdcresponse.htm (accessed on 9 September 2014).
4. Plennevaux, E.; Sheldon, E.; Blatter, M.; Reeves-Hoché M.-K.; Denis, M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: A preliminary report of two randomised controlled phase 2. Lancet2010, 375, 41–48.
5. Nicholson, K.G.; Colegate, A.E.; Podda, A.; Stephenson, I.; Wood, J.; Ypma, E.; Zambon, M.C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357, 1937–1943.
6. Nolan, T.M.; Richmond, P.C.; Skeljo M.V.; Pearce, G.; Hartel G.; Formica, N.T.; Höschler, K.; Bennet, J.; Ryan, D.; Papanaoum, K.; et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008, 26, 4160–4167.
7. Nolan, T.; Richmond, P.C.; Formica, N.T.; Hoschler K.; Skeljo M.V.; Stoney T.; McVernon, J.; Hartel G.; Sawlwin D.C.; Bennet, J.; et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine2008, 26, 6383–6391.
8. Peeters, M.; Regnerb, S.; Vaman, T.; Devaster, J.-M.; Rombo, L. Safety and immunogenicity of an AS03-adjuvanted A (H1N1) pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials. Vaccine 2012, 30, 6483–6491.
9. Wood, J.M.; Dunleavy, U.; Newman, R.W.; Riley, A.M.; Robertson, J.S.; Minor, P.D. The influence of the host cell on standardisation of influenza vaccine potency. Dev. Biol. Stand. 1999, 98, 183–188.
10. Keitel, W.; Groth, N.; Lattanzi, M.; Praus, M.; Hilbert, A.K.; Borkowski, A.; Tsai, T.F. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 trial. Vaccine 2010, 28, 840–848.
11. Keitel, W.A.; Dekker, C.L.; Mink, C.A.; Campbell, J.D.; Edwards, K.M.; Patel, S.M.; Ho, D.Y.; Talbot, H.K.; Guo, K.; Noah, D.L.; et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 2009, 27, 6642–6648.
12. Gordon, D.L.; Sajkov, D.; Woodman, R.J.; Honda-Okubo, Y.; Cox, M.M.J.; Heinzel, S.; Petrovsky, N. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing AdvaxTM polysaccharide adjuvant. Vaccine 2012, 30, 5407–5416.
13. Kelly, H.; Steffens, I. Complexities in assessing the effectiveness of inactivated influenza vaccines. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20403 (accessed on 30 January 2015).
14. Nicoll, A.; Sprenger, M. Low effectiveness undermines promotion of seasonal influenza vaccine. Lancet Inf. Dis. 2013, 13, 7–9.
15. Committee for Medicinal Products for Human Use (CHMP). Explanatory Note on the Withdrawal of the Note for Guidance on Harmonisation of Requirements for Influenza Vaccines and of the Core SmPC/PL for Inactivated Seasonal Influenza Vaccines. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/08/WC500147010.pdf (accessed on 30 January 2015)
16. Stephenson, I.; Das, R.G.; Wood, J.M.; Katz, J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007, 25, 4056–4063.
17. Wood, J.M.; Schild, G.C.; Seagroatt, V. An improved single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand.1977, 5, 237–247.
18. WHO. WHO Expert committee on Biological Standardization. Thirteenth Report; World Health Organization: Geneva, Switzerland, 1979; Annex 3 (WHO Technical Report Series No 638).
19. Wood, J.M.; Mumford, J.A.; Dunleavy, U.; Seagroatt, V; Newman, R.W.; Thornton, D.; Schild, G.C. Single radial immunodiffusion potency tests for inactivated equine influenza vaccines. In Equine Infection Disease V. Proceedings of the Fifth International Conference; Powell, D.G., Ed.; The University Press of Kentucky: KY, USA, 1988; pp. 74–79.
20. WHO: Generic Protocol for the Calibration of Seasonal and Pandemic Influenza Antigen Working Reagents by WHO Essential Regulatory Laboratories World Health Organization Technical Report Series 979 Annex 5 2012. Available online: http://www.who.int/biologicals/areas/vaccines/TRS_979_Annex_5.pdf?ua=1 (accessed on 8 September 2014).
21. Williams, T.L.; Luna, L.; Guo, Z.; Cox, N.J.; Pirkle, N.J.; Donis, R.O.; Barr, J.R. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008, 20, 2510–2520.
22. Harvey, R.; Hamill, M.; Robertson, J.R.; Minor, P.D.; Vodeiko, G.M.; Weir, J.P.Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards. Biologicals 2012, 40, 96–99.
23. Engelhardt, O; Minor, P; Dunleavy, U; Division of Virology, National Institute of Biological Standards and Control, South Mimms, Herts, UK. Unpublished data, 2014.
24. Lorbetskie, B.; Wang, J.; Gravel, C.; Allen, C.; Walsh, M.; Rinfret, A.; Li, X.; Girard, M. Optimization and qualification of a quantitative reversed phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011, 29, 3377–3389.
25. Chuna, S.; Li, C.; Domselaar, G.V.; Wang, J.; Farnsworth, A.; Cuib, X.; Rode, H.; Cyr, T.D.; He, R.; Li, X. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 2008, 26, 6068–6076.
26. Bodle, J.; Verity, E.E.; Ong, C.; Vandenberg, K.; Shaw, R.; Barr, I.G.; Rockman, S. Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: An alternative method to single radial immunodiffusion. Influenza Other Respir. Viruses 2013, 7, 191–200.
27. Indevr Website. Available online: http://indevr.com/2014/07/press-release-2-9-m-award-advance-titer-chip/ (accessed on 9 September 2014).
28. Schmeisser, F.; Vasudevan, A.; Soto, S.; Kumar, A.; Williams, O.; Weir, J.P. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines. Influenza Other Respir. Viruses 2014, 8, 587–595, doi:10.1111/irv.12272.
29. Ekiert, D.C.; Friesen, R.H.E.; Bhabha, G.; Kwaks, T.; Jongeneelen, M.; Yu, W.; Ophorst, C.; Cox, F.; Korse, H.J.; Brandenburg, B.; et al. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses. Science 2011, 333, 843–850.
30. Hufton, S.E.; Risley, P.; Ball, C.R.; Major, D.; Engelhardt, O.G. The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. PLOS ONE 2014, 9, e103294.
31. Cheung, C.; Hufton, S.; Engelhardt, O. Division of Virology, National Institute of Biological Standards and Control, South Mimms, Herts, UK. Personal Communication, 2014.
32. Hashem, A.; Gravel, C.; Farnsworth, A.; Zou, W.; Lemieux, M.; Xu, K.; Li, C.; Wang, J.; Goneau, M.-F.; Merziotis, M.; et al. A novel synthetic receptor-based immunoassay for influenza vaccine quantification. PLOS ONE 2013, 8, e55428.
33. Nilsson, C.E.; Abbas, S.; Bennemo, M.; Larsson, A.; Hämäläinen, M.D.; Frostell-Karlsson, Å. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010, 28, 759–766.
34. Khurana, S.; King, L.R.; Manischewitz, J.; Coyle, E.; Golding, H. Novel rapid antibody-independent receptor binding SPR-based high-throughput assay for measurement of influenza vaccine potency. Vaccine 2014, 32, 2188–2197.
35. Khan, S.; Larkin, C.; Verma, S.; Joshi, M.B.; Fontana, J.; Steven, A.C.; King, L.R.; Manischewitz, J.; McCormick, W.; Gupta, R.K.; et al. Recombinant HA1 produced in E.coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 2011, 29, 5657–5665.